tbuckley/cabot-search huggingface dataset:
CoINcIDE: A framework for discovery of patient subtypes across multiple datasets
Authors: Catherine R. Planey, Olivier Gevaert
Journal: Genome Medicine (2016)

Patient disease subtypes have the potential to transform personalized medicine. However, many patient subtypes derived from unsupervised clustering analyses on high-dimensional datasets are not replicable across multiple datasets, limiting their clinical utility. We present CoINcIDE, a novel methodological framework for the discovery of patient subtypes across multiple datasets that requires no between-dataset transformations. We also present a high-quality database collection, curatedBreastData, with over 2,500 breast cancer gene expression samples. We use CoINcIDE to discover novel breast and ovarian cancer subtypes with prognostic significance and novel hypothesized ovarian therapeutic targets across multiple datasets. CoINcIDE and curatedBreastData are available as R packages.
Development of a prosaposin-derived therapeutic cyclic peptide that targets ovarian cancer via the tumor microenvironment
Authors: Suming Wang, Anna Blois, Tina El Rayes, Joyce F. Liu, Michelle S. Hirsch, Karsten Gravdal, Sangeetha Palakurthi, Diane R. Bielenberg, Lars A. Akslen, Ronny Drapkin, Vivek Mittal, Randolph S. Watnick
Journal: Science Translational Medicine (2016)

A cyclic prosaposin-derived peptide targets ovarian cancer cells through the fatty acid translocase CD36.
Physical and sexual assault histories among psychiatric outpatients
Authors: A Jacobson
Journal: American Journal of Psychiatry (1989)

Using a semistructured interview, the author obtained complete histories of experiences of being physically or sexually assaulted from 31 psychiatric outpatients. The majority (68%) of outpatients had experienced major physical and/or sexual assaults, and most assaults had not been revealed to the patients' prior therapists. Circumstances associated with the assaults, a comparison of outpatient and inpatient assault histories, and the relevance of the findings to clinical practice are discussed.
Abstract 18684: Extracorporeal Shockwave Myocardial Revascularization: A Novel Therapy for Refractory Angina Pectoris
Authors: Megha Prasad, Andrew Cassar, Martin Rodriguez-Porcel, Guy S Reeder, Darshak Karia, Anthony DeMaria, Amir Lerman
Journal: Circulation (2013)

Background: Treatment options for refractory angina not amenable to revascularization are limited. Extracorporeal shockwave myocardial revascularization (ESMR) is a novel non-invasive application of low intensity shock waves that stimulates angiogenesis to improve ischemia. We aimed to determine the safety and efficacy of ESMR in patients with refractory angina. Methods: A single-arm multicenter U.S. prospective trial was implemented to assess safety and efficacy of ESMR therapy in patients with Class III/Class IV refractory angina. Each patient received 9 sessions of ESMR to ischemic areas over 9 weeks. Efficacy was assessed at baseline and 4 months after treatment by maximal treadmill exercise time and ischemic burden on pharmacological single photon emission computed tomography (SPECT). Safety was assessed by incidence of adverse events, electrocardiography, echocardiography, laboratory markers, and pain questionnaires. Results: Fifteen patients with medically refractory angina were enrolled. Exercise treadmill time from baseline to last follow-up after ESMR increased significantly (38%) by 122.3±156.9 seconds (319.8±157.2 vs. 422.1±183.3 seconds, p=0.016) (Figure 1). There was no difference in the mean summed stress score (SSS) on pharmacological-SPECT 4 months after treatment vs. baseline (17.8±14.9 vs. 21.2±15.3, p=0.233). However, SPECT SSS revealed that untreated areas had greater progression in ischemic burden vs. treated areas (3.69±6.2 vs. 0.31±4.5, p=0.038). There was no significant change in the mean summed echo score from baseline to post treatment (0.4±5.1, p=0.79).There were no changes in electrocardiography, echocardiographic parameters, or laboratory markers. No serious adverse events or complications occurred, and pain with ESMR was minimal (score of 0.5±1.2 to 1.1±1.2 out of 10). Conclusions: We find that ESMR is a safe and efficacious treatment which may be clinically feasible for patients with refractory angina pectoris.
Abstract 15042: BioImage Study: Combined Use of Novel Biomarker Panel (CardioSCORE) and Computed Tomography Coronary Calcium Scores in Predicting Major Adverse Cardiovascular Events
Authors: Khurram Nasir, Matthew J Budoff, Pieter Muntendam, Mario J Garcia, Borge Nordestgaard, Erling Falk, Valentin Fuster
Journal: Circulation (2012)

Background: Coronary artery calcification (CAC) measurement has proven consistent for prognostication for adverse cardiac events. In this study we aim to interaction of multi-marker panel of 7 prot...
The prognostic value of hematogones in patients with acute myeloid leukemia
Authors: Sylvain P. Chantepie, Jean‐Jacques Parienti, Véronique Salaun, Khaled Benabed, Stéphane Cheze, Anne‐Claire Gac, Hyacinthe Johnson‐Ansah, Margaret Macro, Gandhi Damaj, Jean‐Pierre Vilque, Oumedaly Reman
Journal: American Journal of Hematology (2016)

In acute myeloid leukemia (AML), new prognostic tools are needed to assess the risk of relapse. Hematogones (HGs) are normal B-lymphocyte precursors that increase in hematological diseases and may influence remission duration in AML. HG detection was prospectively investigated in 262 AML patients to determine its prognostic value. Flow cytometric HG detection was performed in bone marrow aspiration after intensive chemotherapy at the time of hematological recovery. Patients with HGs in bone marrow samples had a significantly better relapse-free survival (RFS) and overall survival (OS) than patients without HGs (P = 0.0021, and P = 0.0016). Detectable HGs independently predicted RFS (HR = 0.61, 95%CI: 0.42 - 0.89, P = 0.012) and OS (HR = 0.59, 95%CI: 0.38 - 0.92, 0.019) controlling for age, ELN classification, the number of chemotherapy cycles to achieve CR, performance status, secondary AML and flow cytometric minimal residual disease (MRD). In intensively treated AML, individual determination of HGs could be useful to stratify the optimal risk-adapted therapeutic strategy after induction chemotherapy. Am. J. Hematol. 91:566-570, 2016. © 2016 Wiley Periodicals, Inc.
Managing acute hamstring injuries in athletes
Authors: Gustaaf Reurink
Journal: British Journal of Sports Medicine (2016)

I investigated (1) the efficacy of platelet-rich plasma (PRP) injections in acute hamstring injuries in athletes and (2) determined the role of MRI in the management of acute hamstring injuries.⇓



Gustaaf Reurink



Acute hamstring injuries are one of the most common sports injuries. Despite this, there was remarkably little evidence from high-quality clinical studies regarding the management of these injuries.

### Treatment of hamstring injury using PRP

In sports and exercise medicine, there is growing attention on interventions that provide endogenous growth factors directly to the injury site. These growth factors are claimed to facilitate healing and speed up the return to play (RTP) after musculoskeletal injury. The most …
Targeting prion-like protein doppel selectively suppresses tumor angiogenesis
Authors: Taslim A. Al-Hilal, Seung Woo Chung, Jeong Uk Choi, Farzana Alam, Jooho Park, Seong Who Kim, Sang Yoon Kim, Fakhrul Ahsan, In-San Kim, Youngro Byun
Journal: Journal of Clinical Investigation (2016)

Controlled and site-specific regulation of growth factor signaling remains a major challenge for current antiangiogenic therapies, as these antiangiogenic agents target normal vasculature as well tumor vasculature. In this article, we identified the prion-like protein doppel as a potential therapeutic target for tumor angiogenesis. We investigated the interactions between doppel and VEGFR2 and evaluated whether blocking the doppel/VEGFR2 axis suppresses the process of angiogenesis. We discovered that tumor endothelial cells (TECs), but not normal ECs, express doppel; tumors from patients and mouse xenografts expressed doppel in their vasculatures. Induced doppel overexpression in ECs enhanced vascularization, whereas doppel constitutively colocalized and complexed with VEGFR2 in TECs. Doppel inhibition depleted VEGFR2 from the cell membrane, subsequently inducing the internalization and degradation of VEGFR2 and thereby attenuating VEGFR2 signaling. We also synthesized an orally active glycosaminoglycan (LHbisD4) that specifically binds with doppel. We determined that LHbisD4 concentrates over the tumor site and that genetic loss of doppel in TECs decreases LHbisD4 binding and targeting both in vitro and in vivo. Moreover, LHbisD4 eliminated VEGFR2 from the cell membrane, prevented VEGF binding in TECs, and suppressed tumor growth. Together, our results demonstrate that blocking doppel can control VEGF signaling in TECs and selectively inhibit tumor angiogenesis.
Relation between <i>in Utero</i> Arsenic Exposure and Birth Outcomes in a Cohort of Mothers and Their Newborns from New Hampshire
Authors: Diane Gilbert-Diamond, Jennifer A. Emond, Emily R. Baker, Susan A. Korrick, Margaret R. Karagas
Journal: Environmental Health Perspectives (2016)

Background:Studies suggest that arsenic exposure influences birth outcomes; however, findings are mixed.Objective:We assessed in utero arsenic exposure in relation to birth outcomes and whether maternal prepregnancy weight and infant sex modified the associations.Methods:Among 706 mother–infant pairs exposed to low levels of arsenic through drinking water and diet, we assessed in utero arsenic exposure using maternal second-trimester urinary arsenic, maternal prepregnancy weight through self-report, and birth outcomes from medical records.Results:Median (interquartile range) of total urinary arsenic [tAs; inorganic arsenic (iAs) + monomethylarsonic acid (MMA) + dimethylarsinic acid (DMA)] was 3.4 μg/L (1.7–6.0). In adjusted linear models, each doubling of tAs was associated with a 0.10-cm decrease (95% CI: –0.19, –0.01) in head circumference. Results were similar for MMA and DMA. Ln(tAs) and ln(DMA) were positively associated with birth length in infant males only; among males, each doubling of tAs was associated with a 0.28-cm increase (95% CI: 0.09, 0.46) in birth length (pinteraction = 0.04). Results were similar for DMA. Additionally, arsenic exposure was inversely related to ponderal index, and associations differed by maternal weight. Each ln(tAs) doubling of tAs was associated with a 0.55-kg/m3 lower (95% CI: –0.82, –0.28, p &lt; 0.001) ponderal index for infants of overweight/obese, but not normal-weight, mothers (pinteraction &lt; 0.01). Finally, there was a significant interaction between maternal weight status, infant sex, and arsenic exposure on birth weight (pinteraction = 0.03). In girls born of overweight/obese mothers, each doubling of tAs was associated with a 62.9-g decrease (95% CI: –111.6, –14.2) in birth weight, though the association was null in the other strata.Conclusions:Low-level arsenic exposure may affect fetal growth, and the associations may be modified by maternal weight status and infant sex.Citation:Gilbert-Diamond D, Emond JA, Baker ER, Korrick SA, Karagas MR. 2016. Relation between in utero arsenic exposure and birth outcomes in a cohort of mothers and their newborns from New Hampshire. Environ Health Perspect 124:1299–1307; http://dx.doi.org/10.1289/ehp.1510065
Nuclear Receptor Corepressor 1 Expression and Output Declines with Prostate Cancer Progression
Authors: Sandra M. Lopez, Alexander I. Agoulnik, Manqi Zhang, Leif E. Peterson, Egla Suarez, Gregory A. Gandarillas, Anna Frolov, Rile Li, Kimal Rajapakshe, Christian Coarfa, Michael M. Ittmann, Nancy L. Weigel, Irina U. Agoulnik
Journal: Clinical Cancer Research (2016)

Castration therapy in advanced prostate cancer eventually fails and leads to the development of castration-resistant prostate cancer (CRPC), which has no cure. Characteristic features of CRPC can be increased androgen receptor (AR) expression and altered transcriptional output. We investigated the expression of nuclear receptor corepressor 1 (NCOR1) in human prostate and prostate cancer and the role of NCOR1 in response to antiandrogens.NCOR1 protein levels were compared between matched normal prostate and prostate cancer in 409 patient samples. NCOR1 knockdown was used to investigate its effect on bicalutamide response in androgen-dependent prostate cancer cell lines and transcriptional changes associated with the loss of NCOR1. NCOR1 transcriptional signature was also examined in prostate cancer gene expression datasets.NCOR1 protein was detected in cytoplasm and nuclei of secretory epithelial cells in normal prostate. Both cytoplasmic and nuclear NCOR1 protein levels were lower in prostate cancer than in normal prostate. Prostate cancer metastases show significant decrease in NCOR1 transcriptional output. Inhibition of LNCaP cellular proliferation by bicalutamide requires NCOR1. NCOR1-regulated genes suppress cellular proliferation and mediate bicalutamide resistance. In the mouse, NCOR1 is required for bicalutamide-dependent regulation of a subset of the AR target genes.In summary, we demonstrated that NCOR1 function declines with prostate cancer progression. Reduction in NCOR1 levels causes bicalutamide resistance in LNCaP cells and compromises response to bicalutamide in mouse prostate in vivo Clin Cancer Res; 22(15); 3937-49. ©2016 AACR.
Abstract 271: Predicting Defibrillation Success Without Interrupting Chest Compression in Cardiac Arrest Patients
Authors: Reza Firoozabadi, Eric Helfenbein, Saeed Babaeizadeh
Journal: Circulation (2013)

Background: In performing CPR on sudden cardiac arrest patients, a balance between chest compressions (CC) and defibrillation is needed. Optimizing the timing of defibrillation shocks may improve outcomes compared to time-based protocols. There exist numerous predictive features computed from the ECG signal before shock delivery to distinguish between rhythms which convert to spontaneous circulation and those which do not. Unfortunately, since CC induce significant artifact on the ECG signal, all these features assume a pause in CC before delivering the shock, so that there is no CC artifact on the ECG signal to be analyzed. However, in the 2010 guidelines, the AHA challenges manufacturers to “seek innovative methods to decrease the amount of time chest compressions are interrupted for AED operation.” It would be beneficial if the predictive features could be calculated while CC are performed and CC artifact is present. Objective: Examine the effects of CC artifact on shock success predictive features and how such effects can be minimized. Methods: A total of 111 short waveform segments from cardiac arrest patients with VF rhythm and transition from CC to hands-off were used. Thirteen temporal and spectral predictive features were calculated on a 4-sec “noisy” interval containing CC artifact preceding the transition at the end of CC, and on the adjacent 4-sec “clean” interval with no CC artifact following the transition. We presumed the underlying VF remained constant during both intervals. Predictive features were then calculated on a “filtered” version of the noisy segments with CC artifact removed using a newly developed method. Results: The Wilcoxon signed-rank paired test showed CC artifact had a significant impact on all predictive features. However, after removal of CC artifact using our filter, the test showed all but one feature gave similar values to those from the “clean” segments. Conclusion: The results demonstrate that CC artifact has a significant impact on shock success predictive features, but that the effect can be minimized using our CC artifact filtering method. Large prospective studies are needed to show if a combination of our filtering method and predictive features can help minimize CC interruptions and improve resuscitation outcomes.
Laparoscopic Lavage vs Primary Resection for Perforated Diverticulitis
Authors: Matteo Mandrioli, Gregorio Tugnoli, Salomone Di Saverio
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Progestogen-only contraception and tubal pregnancies.
Authors: Hawkins Df
Journal: BMJ (1974)

The letter from Mr. J. Bonnar (16 February p. 287) reporting a relatively high incidence of ectopic gestation in patients using progestogen-only oral contraception is of sufficient importance to demand prompt comment.  In our studies of 535 women taking these preparations for a total of 4594 months we have encountered three ectopic gestations.  Case 1. Age 30. Para 5 + 3.  Started chlormadinone acetate .5 mg daily in June 1969.  Irregular menstruation and an incident of abdominal pain 25 September 1969.  Laparotomy 22 October 1969 - left fimbrial ectopic gestation.  Case 2. Age 23 Par 2 + 0.  Started norethinsterone .35 mg daily in April 1969.  Pain 27 June 1970.  Laparotomy 1 July 1970 for ruptured left tubal pregnancy located 3 cm from fimbria.  Case 3. Age 19. Par 2 + 0.  Started megestrol acetate .5 mg in oil daily in January 1971.  Eight weeks amenorrhea and suprapubic pain led to laparoscopic diagnosis of a ruptured left tubal pregnancy on 23 June 1971.  In case 2 the patient admitted to missing some pills but this was not so with cases 1 and 3.  The computed (life table) rates for ectopic gestation are .6 1.2 and 1.0 per 100 woman-years for chlormadinone acetate norethisterone and megestrol aceate in oil respectively- not so high as Mr. Bonnars figure of 2 per cent 100  woman-years but directly comparable with Tietzes calculation of .8-1.2 ectopic pregnancies per 100 woman-years in patients not employing any contraception at all.  We have thus found no evidence that progestogen-only oral contraception tends to cause ectopic gestation.  On the other hand there is little doubt that this procedure has the property of preventing intrauterine pregnancy but not preventing intrauterine pregnancy but not preventing tubal pregnancy - a situtation somewhat resembling that with intrauterine devices.   There were 35 pregnancies in our study of which three were ectopic.  The patient taking progestogen-only oral contraceptives who present with symptoms suggesting early pregnancy would be considered to have an increased risk of ectopic gestation.  The basic significance of these observations seems to have escaped comment.  The mode of action of low-dose progestogens in preventing pregnancy can not as has been claimed be an effect on cervical mucus as this would prevent ectopic pregnancy also.  It seems likely that their direct action on the endometrium is responsible for the contraceptive action.(Full text)
Ambulatory Extracorporeal Membrane Oxygenation
Authors: Ankit Bharat, Duc Thinh Pham, Sunil M. Prasad
Journal: JAMA Surgery (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Phase II study of irinotecan based fourth-line chemotherapy for gefitinib therapy-failed non-small cell lung cancer (NSCLC)
Authors: S. Lee, K. Lee, E. Lee, S. Lee, J. Kim, C. Shin, K. Jung, J. Shim, K. In, K. Kang, S. Yoo
Journal: Journal of Clinical Oncology (2007)

18164 Background: Despite the undoubted gains from EGFR TK inhibitor therapy as 2 nd or 3 rd line chemotherapy, most of them will relapse during treatment. Among these patients, they might be young, with good performance status, and their disease is expressed with only minor symptoms. The objectives of this study were to evaluate the antitumor efficacy and safety of irinotecan based regimen as 4 th line therapy for refractory or recurrent to gefitinib treatment. We report our experience with irinotecan-based 4 th line chemotherapy. Methods: Eligibility required proven NSCLC refractory or recurrent after 3 rd line chemotherapy(gefitinib), measurable lesions by RECIST, and ECOG PS 0–1. Irinotecan (60mg/m 2 , day 1,8,15) and/or cisplatin (60 mg/m 2 , day 1) were administered every four week for at least 2 course. We analyzed for time to tumor progression (TTP) for first, response rates and toxicities. Results: Since June 2004, 17 patients (consisting of 9 with squamous cell, 7 with adeno-, and 1 with NSCLC not further specified) with a median age of 61 years were enrolled, with 1 drop out during treatment. Chemotherapy was administered for a median 2 courses (range 2–6). Median TTP was 91 (range 35–210) days. Two pts achieved a PR and 5 pts a SD. Disease control rate was 41.2%. Response rate was 11.8%. Toxicity of grade 3 or 4 consisted of neutropenia (35.3%), anemia (29.4%), thrombocytopenia (17.7%), nausea (17.6%), and diarrhea (23.5%). There were no treatment related deaths. Conclusions: This irinotecan based chemotherapy for EGFR TK inhinbitor therapy failed NSCLC patients showed promising efficacy with tolerable toxicity. Irinotecan based chemotherapy may be considered a potential therapeutic option for 4 th line chemotherapy in well selected patients. No significant financial relationships to disclose.